Sign Up
OverviewAPI
Eli Lilly plans to build a $2.5 billion manufacturing plant in Germany to expand production capacity for injected medicines, including its weight-loss shot Zepbound. Retail investors have been crowding into Eli Lilly after its weight-loss drug received approval in the U.S. and the U.K. Lilly and Novo Nordisk are facing challenges in meeting the demand for obesity and diabetes therapies, with Novo limiting access to starter doses of its weight-loss drug Wegovy. Lilly's CEO mentioned the company's approach as 'all hands on deck' ahead of the FDA approval of Zepbound.

Ask a question